The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fibrinogen to Albumin Ratio and C-reactive Protein to Albumin Ratio in Juvenile Idiopathic Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06024486
Recruitment Status : Not yet recruiting
First Posted : September 6, 2023
Last Update Posted : October 6, 2023
Sponsor:
Information provided by (Responsible Party):
Maha Sayed Ibrahim Abdelrahman, Assiut University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The fibrinogen to albumin ratio (FAR) and C-reactive protein to albumin ratio (CAR) have emerged as useful biomarkers to predict systemic inflammation. The aim here is to investigate the relation between FAR/CAR and Juvenile arthritis disease activity score (JASDAS27) in Juvenile idiopathic arthritis (JIA)

Condition or disease Intervention/treatment
Juvenile Idiopathic Arthritis Diagnostic Test: fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)

Detailed Description:
The JADAS27 includes a selected count of the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), proximal interphalangeal joints, hips, knees and ankles.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Correlation of Fibrinogen to Albumin Ratio and C-reactive Protein to Albumin Ratio With Disease Activity in Juvenile Idiopathic Arthritis
Estimated Study Start Date : November 1, 2023
Estimated Primary Completion Date : May 1, 2024
Estimated Study Completion Date : July 1, 2024

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
JIA cases
juvenile idiopathic arthritis cases
 Diagnostic Test: fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)
measurement of serum albumin, fibrinogen and CRP
CONTROL
age and sex matched healthy controls
 Diagnostic Test: fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)
measurement of serum albumin, fibrinogen and CRP


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The fibrinogen to albumin ratio [ Time Frame: 3 months ]
    measurement of serum fibrinogen and albumin

  2. The CRP to albumin ratio [ Time Frame: 3 MONTHS ]
    measurement of serum CRP and albumin

  3. Correlation of fibrinogen to albumin and CRP to albumin ratios on one side with disease activity on the other side [ Time Frame: 3 MONTHS ]
    correlation of these ratios with JADAS27


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
All juvenile idiopathic arthritis fulfilling the criteria of International League of Associations for Rheumatology (ILAR) and age and sex matched healthy subjects.
Criteria

Inclusion Criteria:

  • All juvenile idiopathic arthritis fulfilling the criteria of International League of Associations for Rheumatology (ILAR) and age and sex matched healthy subjects

Exclusion Criteria:

  • Other systemic inflammatory or autoimmune disorders.
  • History of corticosteroid medication in the last 6 months.
  • Liver diseases.
  • Malignancy.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

No Contacts or Locations Provided
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Maha Sayed Ibrahim Abdelrahman, principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT06024486    
Other Study ID Numbers: Juvenile arthritis assiut u
First Posted: September 6, 2023    Key Record Dates
Last Update Posted: October 6, 2023
Last Verified: October 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
 Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases